ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)

Summary

The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.

Timeline

Start

2022-11-15

Primary completion

2024-03-26

Completion

2024-06-17

Publications

• Xiong Y, Meng X, Jin A, Campbell BCV, Xu A, Dong Q, Xu Y, Pan Y, Jiang Y, Niu S, Li Z, Zhuang X, Guo N, Yuan Z, Kong Z, Zong L, Duan C, Cao Z, Wang L, Hao M, Wu S, Feng X, Li H, Wu N, Li Z, Zhao X, Wang Y; PUMICE Investigators. Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke: The PUMICE Randomized Clinical Trial. JAMA Neurol. 2025 Mar 1;82(3):258-266. doi: 10.1001/jamaneurol.2024.4688.
• Xiong Y, Hao M, Pan Y, Duan C, Feng X, Li H, Wu N, Wang L, Meng X, Zhao X, Wang Y; PUMICE investigators*. Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial. Stroke Vasc Neurol. 2024 Dec 30;9(6):715-722. doi: 10.1136/svn-2023-002673.

Drugs

Indications